Back to results
US 2026/0115138 A1Published application
Lipid nanoparticles
AssigneeCodeBridgeBio Inc.
InventorsOscar R. Miranda, Haitao Zhao, Xiaofeng Sun
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Claims21
A lipid nanoparticle comprising:
- (i) a PEG-conjugated phospholipid having two or more C12-C30 aliphatic chains, at least one of which includes from 1-5 sites of unsaturation;
- (ii) an ionizable lipid having at least two C11-C30 aliphatic chains and a head group that protonates to a cationic moiety having a pKa of 5-7;
- (iii) a non-cationic phospholipid having at least two C11-C30 aliphatic chains and a head group that remains a zwitterion or anion across a pH range of 6 to 8;
- and
- (iv) a sterol, fat-soluble steroid, or vitamin.
2 more elements
A lipid nanoparticle comprising:
- (i) a PEG-conjugated phospholipid having two or more alkyl chains, at least one of which includes from 1-5 sites of unsaturation, and a head group substituted with a polyethylene glycol polymer, wherein the polyethylene glycol polymer has 2-50 polyethylene glycol subunits;
- (ii) a cationic lipid having a cationic head group and two or more C11-C30 aliphatic chains, at least one of which includes from 1-5 sites of unsaturation, wherein the aliphatic chains are attached to the headgroup through a biodegradable linker;
- (iii) a non-cationic phospholipid that remains a zwitterion or anion across a pH range of 6 to 8, having two or more C11-C30 aliphatic chains;
- and
- (iv) a sterol, fat-soluble steroid, or vitamin.
2 more elements
21-48. (canceled)
Dependencies are inferred from the claim text.